Registry of Lipid Control and the Use of Lipid-lowering Drugs for Secondary Prevention of Cardiovascular Events in Patients with Established Atherosclerotic Disease in Taiwan: Rationality and Methods

Background: Dyslipidemia is an important but modifiable risk factor of cardiovascular disease (CVD). However, no nationwide registry has been designed so far to document the inter-relationship between long-term clinical outcomes and the lipid control, and the use of lipid-lowering agents for seconda...

Full description

Bibliographic Details
Main Authors: Wei-Hsian Yin, Chau-Chung Wu, Jaw-Wen Chen
Format: Article
Language:English
Published: Taiwan Society of Geriatric Emergency and Critical Medicine (TSGECM) 2012-12-01
Series:International Journal of Gerontology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S187395981200107X
id doaj-44751f5397fb4594a2a33f8dc250c557
record_format Article
spelling doaj-44751f5397fb4594a2a33f8dc250c5572020-11-25T01:01:13ZengTaiwan Society of Geriatric Emergency and Critical Medicine (TSGECM)International Journal of Gerontology1873-95982012-12-016424124610.1016/j.ijge.2012.09.001Registry of Lipid Control and the Use of Lipid-lowering Drugs for Secondary Prevention of Cardiovascular Events in Patients with Established Atherosclerotic Disease in Taiwan: Rationality and MethodsWei-Hsian Yin0Chau-Chung Wu1Jaw-Wen Chen2Division of Cardiology, Heart Centre, Cheng-Hsin General Hospital, Taipei, TaiwanDivision of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, TaiwanDepartment of Medical Research and Education, Taipei Veterans General Hospital, Taipei, TaiwanBackground: Dyslipidemia is an important but modifiable risk factor of cardiovascular disease (CVD). However, no nationwide registry has been designed so far to document the inter-relationship between long-term clinical outcomes and the lipid control, and the use of lipid-lowering agents for secondary prevention of cardiovascular events in patients with established CVD in a large representative sample of public and private hospitals in Taiwan. Methods: In this registry-type prospective observational study, we sought to record information with regard to the secondary prevention of patients with stable symptomatic atherosclerotic disease, classified by the presence of one of the following conditions: evidence of coronary artery disease, cerebrovascular disease, or peripheral vascular disease, focusing on lipid management, and long-term outcomes. The data on customary Taiwanese clinical practice applied to outpatients will be collected from 14 centers across Taiwan, including public and private hospitals, and will be clinically followed for 5 years after their inclusion. Results: The analysis of this multicenter registry will demonstrate the treatment patterns, goal attainment, factors influencing treatment, and the clinical outcomes among patients suffering from CVD in Taiwan. Conclusions: The registry may increase our understanding of the prevalence and consequences of atherothrombosis on a nationwide basis. In addition to academic interests, the results may have impact on future clinical practice pattern and national policy on lipid management in Taiwan.http://www.sciencedirect.com/science/article/pii/S187395981200107Xatherosclerosiscardiovascular diseaseslipid-lowering drugslipid managementrisk factors
collection DOAJ
language English
format Article
sources DOAJ
author Wei-Hsian Yin
Chau-Chung Wu
Jaw-Wen Chen
spellingShingle Wei-Hsian Yin
Chau-Chung Wu
Jaw-Wen Chen
Registry of Lipid Control and the Use of Lipid-lowering Drugs for Secondary Prevention of Cardiovascular Events in Patients with Established Atherosclerotic Disease in Taiwan: Rationality and Methods
International Journal of Gerontology
atherosclerosis
cardiovascular diseases
lipid-lowering drugs
lipid management
risk factors
author_facet Wei-Hsian Yin
Chau-Chung Wu
Jaw-Wen Chen
author_sort Wei-Hsian Yin
title Registry of Lipid Control and the Use of Lipid-lowering Drugs for Secondary Prevention of Cardiovascular Events in Patients with Established Atherosclerotic Disease in Taiwan: Rationality and Methods
title_short Registry of Lipid Control and the Use of Lipid-lowering Drugs for Secondary Prevention of Cardiovascular Events in Patients with Established Atherosclerotic Disease in Taiwan: Rationality and Methods
title_full Registry of Lipid Control and the Use of Lipid-lowering Drugs for Secondary Prevention of Cardiovascular Events in Patients with Established Atherosclerotic Disease in Taiwan: Rationality and Methods
title_fullStr Registry of Lipid Control and the Use of Lipid-lowering Drugs for Secondary Prevention of Cardiovascular Events in Patients with Established Atherosclerotic Disease in Taiwan: Rationality and Methods
title_full_unstemmed Registry of Lipid Control and the Use of Lipid-lowering Drugs for Secondary Prevention of Cardiovascular Events in Patients with Established Atherosclerotic Disease in Taiwan: Rationality and Methods
title_sort registry of lipid control and the use of lipid-lowering drugs for secondary prevention of cardiovascular events in patients with established atherosclerotic disease in taiwan: rationality and methods
publisher Taiwan Society of Geriatric Emergency and Critical Medicine (TSGECM)
series International Journal of Gerontology
issn 1873-9598
publishDate 2012-12-01
description Background: Dyslipidemia is an important but modifiable risk factor of cardiovascular disease (CVD). However, no nationwide registry has been designed so far to document the inter-relationship between long-term clinical outcomes and the lipid control, and the use of lipid-lowering agents for secondary prevention of cardiovascular events in patients with established CVD in a large representative sample of public and private hospitals in Taiwan. Methods: In this registry-type prospective observational study, we sought to record information with regard to the secondary prevention of patients with stable symptomatic atherosclerotic disease, classified by the presence of one of the following conditions: evidence of coronary artery disease, cerebrovascular disease, or peripheral vascular disease, focusing on lipid management, and long-term outcomes. The data on customary Taiwanese clinical practice applied to outpatients will be collected from 14 centers across Taiwan, including public and private hospitals, and will be clinically followed for 5 years after their inclusion. Results: The analysis of this multicenter registry will demonstrate the treatment patterns, goal attainment, factors influencing treatment, and the clinical outcomes among patients suffering from CVD in Taiwan. Conclusions: The registry may increase our understanding of the prevalence and consequences of atherothrombosis on a nationwide basis. In addition to academic interests, the results may have impact on future clinical practice pattern and national policy on lipid management in Taiwan.
topic atherosclerosis
cardiovascular diseases
lipid-lowering drugs
lipid management
risk factors
url http://www.sciencedirect.com/science/article/pii/S187395981200107X
work_keys_str_mv AT weihsianyin registryoflipidcontrolandtheuseoflipidloweringdrugsforsecondarypreventionofcardiovasculareventsinpatientswithestablishedatheroscleroticdiseaseintaiwanrationalityandmethods
AT chauchungwu registryoflipidcontrolandtheuseoflipidloweringdrugsforsecondarypreventionofcardiovasculareventsinpatientswithestablishedatheroscleroticdiseaseintaiwanrationalityandmethods
AT jawwenchen registryoflipidcontrolandtheuseoflipidloweringdrugsforsecondarypreventionofcardiovasculareventsinpatientswithestablishedatheroscleroticdiseaseintaiwanrationalityandmethods
_version_ 1725210126498922496